San Francisco Bay Area biotech stories.
Wednesday, February 15, 2012
Stock offering nets Exelixis $65 million
Exelixis Inc. will net $65 million by selling 12.65 million shares of common stock, the South San Francisco biotech cancer drug developer said Wednesday.
The total includes 1.65 million shares that the underwriters opted to buy.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)